152 related articles for article (PubMed ID: 20407731)
1. Simultaneous electrochemical detection of both PSMA (+) and PSMA (-) prostate cancer cells using an RNA/peptide dual-aptamer probe.
Min K; Song KM; Cho M; Chun YS; Shim YB; Ku JK; Ban C
Chem Commun (Camb); 2010 Aug; 46(30):5566-8. PubMed ID: 20407731
[TBL] [Abstract][Full Text] [Related]
2. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.
Lupold SE; Hicke BJ; Lin Y; Coffey DS
Cancer Res; 2002 Jul; 62(14):4029-33. PubMed ID: 12124337
[TBL] [Abstract][Full Text] [Related]
4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
6. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
Kim D; Jeong YY; Jon S
ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric detection of prostate tumor cells using chemoaffinity labels.
Wu LY; Liu T; Grimm AL; Davis WC; Berkman CE
Prostate; 2011 Jan; 71(1):52-61. PubMed ID: 20632319
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade.
Schmidt B; Anastasiadis AG; Seifert HH; Franke KH; Oya M; Ackermann R
Anticancer Res; 2003; 23(5A):3991-9. PubMed ID: 14666708
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer.
Ptacek J; Zhang D; Qiu L; Kruspe S; Motlova L; Kolenko P; Novakova Z; Shubham S; Havlinova B; Baranova P; Chen SJ; Zou X; Giangrande P; Barinka C
Nucleic Acids Res; 2020 Nov; 48(19):11130-11145. PubMed ID: 32525981
[TBL] [Abstract][Full Text] [Related]
10. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.
Tse BW; Cowin GJ; Soekmadji C; Jovanovic L; Vasireddy RS; Ling MT; Khatri A; Liu T; Thierry B; Russell PJ
Nanomedicine (Lond); 2015 Feb; 10(3):375-86. PubMed ID: 25407827
[TBL] [Abstract][Full Text] [Related]
11. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Minner S; Wittmer C; Graefen M; Salomon G; Steuber T; Haese A; Huland H; Bokemeyer C; Yekebas E; Dierlamm J; Balabanov S; Kilic E; Wilczak W; Simon R; Sauter G; Schlomm T
Prostate; 2011 Feb; 71(3):281-8. PubMed ID: 20809553
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
13. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE
J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850
[TBL] [Abstract][Full Text] [Related]
14. Re: PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.
Wiwanitkit S
Int Braz J Urol; 2014; 40(2):285; author reply 286. PubMed ID: 24856501
[No Abstract] [Full Text] [Related]
15. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
O'Keefe DS; Bacich DJ; Heston WD
Prostate; 2004 Feb; 58(2):200-10. PubMed ID: 14716746
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity.
Kawatani M; Yamamoto K; Yamada D; Kamiya M; Miyakawa J; Miyama Y; Kojima R; Morikawa T; Kume H; Urano Y
J Am Chem Soc; 2019 Jul; 141(26):10409-10416. PubMed ID: 31244179
[TBL] [Abstract][Full Text] [Related]
17. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
18. PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
Bao K; Lee JH; Kang H; Park GK; El Fakhri G; Choi HS
Chem Commun (Camb); 2017 Feb; 53(10):1611-1614. PubMed ID: 28085163
[TBL] [Abstract][Full Text] [Related]
19. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
20. [New Radiopharmaceuticals Based on Prostate-Specific Inhibitors of Membrane Antigen for Diagnostics and Therapy of Metastatic Prostate Cancer].
Vlasova OP; German KE; Krilov VV; Petriev VM; Epstein NB
Vestn Ross Akad Med Nauk; 2015; (3):360-5. PubMed ID: 26495726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
